Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon alpha-2 beta and vinblastine

Urology

Volumn 48, Issue 3, 1996, Pages 373-378

  Papadopoulos, Ilias ^a   Rudolph, Pierre ^a   Weichert Jacobsen, Klaus ^a   Thiemann, Oliver ^a   Papadopoulou, Doris ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; DRUG EFFICACY; DRUG INFUSION; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030249295     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00168-9     Document Type: Article

References (25)

1. Buzaid AC, and Todd MB: Therapeutic options in renal cell carcinoma. Semin Oncol [Suppl] 16: 12-19, 1989.
2. Giuliani L, Giberti C, Martorana G, and Rovida S: Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 143: 468-474, 1990.
3. Schmitz-Dräger BJ, Jankevicius F, and Otto T: Prognostische Faktoren zur Vorhersage des Erfolges einer Immuntherapie beim metastasierten Nierenzellkarzinom [Prognostic factors for predicting the success of immunotherapy in metastatic renal cell carcinoma]. Urologe [A] 34: 195-199, 1995.
4. Elson PJ, Witte RS, and Trump DL: Prognostic factors for survival in patients with incurrent or metastatic renal cell carcinoma. Cancer Res 48: 7310-7313, 1988.
5. Mani S, Todd MB, Katz K, and Poo WJ: Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 154: 35-40, 1995.
6. Cavazzana AO, Prayer-Galetti T, Sangiorgio A, Fassina AS, Panozzo M, Zucchetta P, and Pagano F: DNA content, nuclear grading and early tumor progression in renal cell cancer: a prospective study on frozen specimens. Eur Urol 22: 311-315, 1992.
7. Currin SM, Lee SE, and Walther PJ: Flow cytometric assessment of deoxyribonucleic acid content in renal adenocarcinoma: does ploidy status enhance prognostic stratification over stage alone? J Urol 143: 458-461, 1990.
8. Papadopoulos I, Weichert-Jacobsen K, Sprenger E, and Wacker HH: DNA content and the proliferation marker Ki-67 as prognostic indicators in renal cell carcinoma. Urol Int 53: 181-185, 1994.
9. Lissoni P, Barni S, Ardizzoia A, Crispino S, Paolorossi F, Andres M, Scardino E, and Tancini G: Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma. Oncology 51: 59-62, 1994.
10. Thoenes W, Störkel S, and Rumpelt HJ: Histopathology and classification of renal cell tumors (adenomas, oncocytonias and carcinomas): the basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 181: 125-143, 1986.
11. Union International Centre Cancer: TNM Classification of Malignant Tumours, 2nd ed. Geneva, UICC, 1982.
12. Rudolph P, Lappe T, Schubert C, Schmidt D, Parwaresch RM, and Christophers E: Diagnostic assessment of two novel proliferation specific antigens in benign and malignant melanocytic lesions. Am J Pathol 147: 1615-1625, 1995.
13. Shi SR, Key ME, and Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave ovenheating of tissue sections. J Histochem Cytochem 39: 741-748, 1991.
14. Schmidt D, Wischmeyer P, Leuschner I, Sprenger E, Langenau E, von Schweinitz D, and Harms D: DNA analysis in hepatoblastoma by flow and image cytometry. Cancer 72: 2914-2919, 1993.
15. Feichter GE, Goerttler K, and Haag D: DNA-Messung von malignent umioven mittels Impulszytophotometric. Dtsch Med Wochenschr 109:738-744, 1984.
16. Angus R, Collins CM, and Symes MO: The effect of alpha and gamma Interferon on cell growth and histocompatibility antigen expression by human renal carcinoma cells in vitro. Eur J Cancer 29: 1879-1885, 1993.
17. Kempf RA, Grunberg SM, and Daniels JR: Recombinant Interferon alpha 2 in a phase II study of renal cell carcinoma. Proc Am Soc Clin Oncol 3: 59-63, 1984.
18. Schornagel JH, Verweij J, ten Bokkel Huinink WW, Klijn JGM, de Mulder PHM, Debruyne FMJ, van Deijk WA, Roozendaal K, Kok TC, Veenhof KHN, et al: Phase II study of recombinant Interferon alpha-2A and vinblastine in advanced renal cell carcinoma. J Urol 142: 253-256, 1989.
19. Papadopoulos I, and Wand H: Treatment of adenocarcinoma of the kidney with interferone a-2b and vinblastine. Hell Urology 3: 287-293, 1991.
20. Bergerat JP, Herbrecht R, and Dufour P: Combination of recombinant interferon alpha-2a and vinblastine in advanced renal cell cancer. Cancer 62: 2320-2324, 1988.
21. von Rohr A, Ghosh AK, Thatcher N, and Stern PL: Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy. Br J Cancer 67: 163-171, 1993.
22. Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, et al: A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 10: 275-281, 1992.
23. Hofmockel G, Wirth MP, Heimbach D, and Frohmüller HGW: Ergebnisse der niedrig dosierten zyklischen Interferon-Gamma Therapie beim metastasierten Nierenzell-karzinom [Results of low dosage cyclic interferon-gamma therapy of metastatic renal cell carcinoma]. Urologe [A] 32: 290-294, 1993.
24. Gross AJ, Dieckmann KP, Krain J, and Huland H: Individualspezifische Therapie mit alpha-Interferon beim metastasierten Nierenzellkarzinom [Individualized therapy with alpha-interferon in metastic renal cell carcinoma]. Urologe [A] 34: 158-161, 1995.
25. Gerdes J: Ki-67 and other proliferations markers useful for immunohistochemical diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol 1: 199-206, 1990.